Evicenter
MarkdownMedical informationP&T meetings
Psilocybin (COMP360)

Treatment-resistant depression

Manufacturer
COMPASS Pathways
Last updated
261 sources

Section 1 of 6

Terms and abbreviations

1 evidence topic · 0 sources

AbbreviationTerm
5-HT5-hydroxytryptamine (serotonin)
5-HT2A5-hydroxytryptamine 2A receptor
ACPAmerican College of Physicians
AEAdverse event
AHFSAmerican Hospital Formulary Service
ASCAltered States of Consciousness questionnaire
ATRQAntidepressant Treatment Response Questionnaire
AUCArea under the concentration-time curve
BDI-IIBeck Depression Inventory, second edition
BMIBody mass index
BPBlood pressure
C-SSRSColumbia-Suicide Severity Rating Scale
CANMATCanadian Network for Mood and Anxiety Treatments
CANTABCambridge Neuropsychological Test Automated Battery
CBTCognitive behavioral therapy
CCAECommercial Claims and Encounters database
CCTVClosed-circuit television
CFBChange from baseline
CGI-IClinical Global Impression-Improvement
CGI-SClinical Global Impression-Severity
CIConfidence interval
CMSCenters for Medicare & Medicaid Services
CNPVCommissioner's National Priority Voucher
CPSMCompass Psychological Support Model
CPTCurrent Procedural Terminology
CRPC-reactive protein
DBSDeep brain stimulation
DEADrug Enforcement Administration
DLPFCDorsolateral prefrontal cortex
DMNDefault mode network
DoDDepartment of Defense
DSM-5Diagnostic and Statistical Manual of Mental Disorders, fifth edition
DTDDifficult-to-treat depression
ECTElectroconvulsive therapy
EMAEuropean Medicines Agency
EQ-5DEuroQol 5-dimension questionnaire
EQ-VASEuroQol visual analogue scale
ESKEsketamine
FDAU.S. Food and Drug Administration
GAD-7Generalized Anxiety Disorder 7-item scale
HAM-DHamilton Depression Rating Scale
HCPHealthcare professional
HDRSHamilton Depression Rating Scale
HEDISHealthcare Effectiveness Data and Information Set
HIAAHydroxyindoleacetic acid
HRHazard ratio
HRQoLHealth-related quality of life
HRUHealthcare resource utilization
ICERInstitute for Clinical and Economic Review
IDS-SR-30Inventory of Depressive Symptomatology, Self-Report, 30-item
ILAPInnovative Licensing and Access Pathway
IQRInterquartile range
IRRIncidence rate ratio
ITTIntention-to-treat
IVIntravenous
LSDLysergic acid diethylamide
LSMDLeast squares mean difference
MACEMajor adverse cardiovascular events
MADRSMontgomery-Åsberg Depression Rating Scale
MAOIMonoamine oxidase inhibitor
MCIDMinimal clinically important difference
MDDMajor depressive disorder
MDEMajor depressive episode
MDMA3,4-Methylenedioxymethamphetamine
MedDRAMedical Dictionary for Regulatory Activities
MHRAMedicines and Healthcare products Regulatory Agency
MINIMini International Neuropsychiatric Interview
MSMMaudsley Staging Model
MTIMaudsley Treatment Inventory
NDANew Drug Application
NHSNational Health Service
NICENational Institute for Health and Care Excellence
NMDAN-methyl-D-aspartate
NNHNumber needed to harm
NNTNumber needed to treat
NSDUHNational Survey on Drug Use and Health
OROdds ratio
PETPictorial Empathy Test
PHQ-9Patient Health Questionnaire 9-item
PKPharmacokinetics
PPPYPer patient per year
PTSDPosttraumatic stress disorder
Q-LES-QQuality of Life Enjoyment and Satisfaction Questionnaire
QALYQuality-adjusted life-year
QIDS-SRQuick Inventory of Depressive Symptomatology, Self-Report
QTcFQT interval corrected by Fridericia's formula
RCTRandomized controlled trial
REMSRisk Evaluation and Mitigation Strategy
RMETReading the Mind in the Eyes Test
RRRelative risk
rTMSRepetitive transcranial magnetic stimulation
SAESerious adverse event
SDStandard deviation
SDSSheehan Disability Scale
SEStandard error
SGASecond-generation antipsychotic
SMDStandardized mean difference
SNRISerotonin-norepinephrine reuptake inhibitor
SNTStanford Neuromodulation Therapy
SSRScale of Social Responsibility
SSRISelective serotonin reuptake inhibitor
SVOSocial Value Orientation
TAUTreatment as usual
TCATricyclic antidepressant
TEAETreatment-emergent adverse event
TEQToronto Empathy Questionnaire
TESAETreatment-emergent serious adverse event
TMSTranscranial magnetic stimulation
TRDTreatment-resistant depression
UGTUridine 5'-diphospho-glucuronosyltransferase
VADepartment of Veterans Affairs
VNSVagus nerve stimulation
WACWholesale acquisition cost
WPAIWork Productivity and Activity Impairment questionnaire
WSASWork and Social Adjustment Scale
XRExtended release